Cover Image

Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)

Massimo Travaglini,1 Julia-Tatjana Maul,2,3 Christian Kors,4 Shirin Zaheri,5 Jens Gerwien,6 Michaela Müller,6 Alan Brnabic,6 Silvia Sabatino,6 Christopher Schuster,6,7 Tsen-Fang Tsai8 1Centre for the Treatment of Psoriasis, Di Summa-Perrino Hospital, Brindisi, Italy; 2Department of Dermatology and V...

Full description

Saved in:

Bibliographic Details
Main Authors:	Travaglini M (Author), Maul JT (Author), Kors C (Author), Zaheri S (Author), Gerwien J (Author), Müller M (Author), Brnabic A (Author), Sabatino S (Author), Schuster C (Author), Tsai TF (Author)
Format:	Book
Published:	Dove Medical Press, 2023-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
by: A. Pinter, et al.
Published: (2023)

Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
by: A. Pinter, et al.
Published: (2024)

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
by: April W. Armstrong, et al.
Published: (2024)

Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
by: Elisabeth Riedl, et al.
Published: (2024)

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
by: Andreas Pinter, et al.
Published: (2024)

Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
by: Lisa Schaeffer, et al.
Published: (2024)

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
by: April W. Armstrong, et al.
Published: (2024)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis
by: Rachael M. Hewitt, et al.
Published: (2021)

Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare)
by: C. D. Wortman, et al.
Published: (2024)

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024)

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
by: Jean-Philippe Lacour, et al.
Published: (2020)

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024)

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience-IL PSO (Italian Landscape Psoriasis)
by: Diego Orsini, et al.
Published: (2024)

CLINICAL OUTCOME MEASURES OF PSORIASIS
by: E. Berardesca, et al.
Published: (2011)

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
by: Anzengruber F, et al.
Published: (2018)

Patient needs in women of childbearing age with psoriasis: retrospective analysis from the German PsoBest registry
by: Neuza da Silva Burger, PhD, et al.
Published: (2024)

Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021
by: Evelyn Meulewaeter, et al.
Published: (2024)

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis)
by: D. Orsini, et al.
Published: (2024)

Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
by: Seemal R. Desai, et al.
Published: (2023)

Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare)
by: Marthe-Lisa Schaarschmidt, et al.
Published: (2017)

Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries
by: Valencia López MJ, et al.
Published: (2024)

The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis
by: Carole Guillet, MD, et al.
Published: (2022)

Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab
by: Jared Liu, et al.
Published: (2022)

Aberrant B-cell Subsets and Immunoglobulin Levels in Patients with Moderate-to-severe Psoriasis
by: Katrin Kahlert, et al.
Published: (2018)

Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis
by: Liu X, et al.
Published: (2024)

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study
by: Pablo de laCueva, et al.
Published: (2023)

PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
by: Anna Langenbruch, et al.
Published: (2023)

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort
by: Thomas Bettuzzi, et al.
Published: (2022)

Outcomes among scalp psoriasis patients: Is scalp psoriasis resistant to topical treatment?
by: Toral S Vaidya, et al.
Published: (2018)

Updates on the Treatment of Erythrodermic Psoriasis
by: Lo Y, et al.
Published: (2021)

Interaction of psoriasis and pregnancy: Maternal and fetal outcomes
by: Sevgi Akarsu
Published: (2020)

Viewing Psoriasis as a Systemic Disease for Better Health Outcomes
by: George C. Gondo, et al.
Published: (2021)

A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project
by: Francesco Cusano, et al.
Published: (2022)

Need for individualized counseling regarding psoriasis systemic therapy in women of childbearing age: analysis of the PsoFem study at the University Medical Center Hamburg
by: Brigitte Stephan, MD, et al.
Published: (2024)

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
by: April W. Armstrong, et al.
Published: (2024)

Outcome of psoriasis vulgaris on a child with localized scleroderma
by: Mariem Mohamed, et al.
Published: (2017)

Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
by: Julia-Tatjana Maul, et al.
Published: (2024)

Verrucous Psoriasis - Atypical Variant of Psoriasis Vulgaris
by: Akshaya R.C, et al.
Published: (2022)

Improving patient outcomes in psoriasis: strategies to ensure treatment adherence
by: Yélamos O, et al.
Published: (2015)

Psoriasis y notalgia parestésica Psoriasis and notalgia paresthetica
by: C Farfan, et al.
Published: (2010)